Bergom, Hannah E.
Shabaneh, Ashraf
Day, Abderrahman http://orcid.org/0000-0002-3338-5088
Ali, Atef
Boytim, Ella
Tape, Sydney
Lozada, John R.
Shi, Xiaolei
Kerkvliet, Carlos Perez
McSweeney, Sean
Pitzen, Samuel P. http://orcid.org/0000-0001-6556-0461
Ludwig, Megan
Antonarakis, Emmanuel S.
Drake, Justin M.
Dehm, Scott M. http://orcid.org/0000-0002-7827-5579
Ryan, Charles J.
Wang, Jinhua
Hwang, Justin http://orcid.org/0000-0003-1686-7103
Funding for this research was provided by:
American Cancer Society (IRG-21-049-61-IRG)
Ray of Light Award
Article History
Received: 10 June 2022
Accepted: 3 April 2023
First Online: 14 April 2023
Competing interests
: E.S.A. is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, Eli Lilly, Bayer, AstraZeneca, Bristol Myers Squibb, ESSA, Clovis, Merck, Curium, Blue Earth Diagnostics, Foundation Medicine, Exact Sciences and Invitae; has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers Squibb, Constellation, Bayer, AstraZeneca, Clovis and Merck; and is the coinventor of a patented AR-V7 biomarker technology that has been licensed to Qiagen. J.H is a paid consultant/advisor to Caris Life Sciences and Astrin Biosciences J.M.D. is Chief Scientific Officer and owns stock options at Astrin Biosciences. The other authors declare no competing interests.